Clinical Trial Update: Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update examines capecitabine metronomic chemotherapy combined with an aromatase inhibitor for postmenopausal women with hormone recepto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Capecitabine (capecitabine)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN